Name: MC-VC-PABC-MMAE
Brand: BOC Sciences
Rating: 5 (1 reviews)

Size

Price

Stock

Quantity

$--

In stock

Synonyms

MC-Val-Cit-PABC-MMAE; N-[[[4-[[N-[6-(2,5-Dioxo-1-pyrrolidinyl)-1-oxohexyl]-L-valyl-N5-(aminocarbonyl)-L-ornithyl]amino]phenyl]methoxy]carbonyl]-N-methyl-L-valyl-N-[(1S,2R)-4-[(2S)-2-[(1R,2R)-3-[[(1R,2S)-2-hydroxy-1-methyl-2-phenylethyl]amino]-1-methoxy-2-methyl-3-oxopropyl]-1-pyrrolidinyl]-2-methoxy-1-[(1S)-1-methylpropyl]-4-oxobutyl]-N-methyl-L-valinamide

IUPAC Name

[4-[[(2S)-5-(carbamoylamino)-2-[[(2S)-2-[6-(2,5-dioxopyrrolidin-1-yl)hexanoylamino]-3-methylbutanoyl]amino]pentanoyl]amino]phenyl]methyl N-[(2S)-1-[[(2S)-1-[[(3R,4S,5S)-1-[(2S)-2-[(1R,2R)-3-[[(1S,2R)-1-hydroxy-1-phenylpropan-2-yl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-methylamino]-3-methyl-1-oxobutan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]-N-methylcarbamate

Canonical SMILES

[C@H]([C@H](C(N[C@@H]([C@@H](O)C1=CC=CC=C1)C)=O)C)(OC)[C@]2(N(C(C[C@H]([C@@H](N(C([C@@H](NC([C@@H](N(C(OCC3=CC=C(NC([C@@H](NC([C@@H](NC(CCCCCN4C(=O)CCC4=O)=O)[C@H](C)C)=O)CCCNC(N)=O)=O)C=C3)=O)C)C(C)C)=O)[C@H](C)C)=O)C)[C@H](CC)C)OC)=O)CCC2)[H]

InChI

InChI=1S/C68H107N11O15/c1-15-43(8)59(51(92-13)38-55(83)78-37-23-27-50(78)61(93-14)44(9)62(85)71-45(10)60(84)47-24-18-16-19-25-47)76(11)66(89)57(41(4)5)75-65(88)58(42(6)7)77(12)68(91)94-39-46-29-31-48(32-30-46)72-63(86)49(26-22-35-70-67(69)90)73-64(87)56(40(2)3)74-52(80)28-20-17-21-36-79-53(81)33-34-54(79)82/h16,18-19,24-25,29-32,40-45,49-51,56-61,84H,15,17,20-23,26-28,33-39H2,1-14H3,(H,71,85)(H,72,86)(H,73,87)(H,74,80)(H,75,88)(H3,69,70,90)/t43-,44+,45+,49-,50-,51+,56-,57-,58-,59-,60+,61+/m0/s1

InChIKey

IEDXPSOJFSVCKU-HOKPPMCLSA-N

Density

1.191±0.06 g/cm3

Boiling Point

1359.123±65.00 °C at 760 mmHg

MC-VC-PABC is a versatile peptide-drug conjugate (PDC) that is particularly useful in targeted cancer therapy. The conjugate features a cleavable valine-citrulline (VC) linker, which is sensitive to the enzymes overexpressed in tumor environments. This linker enables selective release of the cytotoxic drug, ensuring that the therapeutic agent is activated directly at the site of the tumor. By minimizing the exposure of healthy tissues to the drug, MC-VC-PABC significantly reduces systemic toxicity while maintaining high efficacy in killing cancer cells. This targeted approach enhances the overall therapeutic index of the drug.

Another significant application of MC-VC-PABC is in drug delivery optimization. The peptide component of the conjugate plays a key role in guiding the drug to specific cancer cells, while the VC linker ensures that the drug is only activated within the tumor. This targeted delivery system improves the pharmacokinetics of the drug by prolonging its circulation time and increasing its accumulation at the tumor site. The controlled release mechanism enhances the drug’s therapeutic efficacy and minimizes unwanted side effects, offering a more efficient alternative to conventional chemotherapy.

MC-VC-PABC also demonstrates promise in combination therapies. When combined with other chemotherapeutic agents or immune therapies, MC-VC-PABC can act synergistically to increase the overall treatment effectiveness. The targeted delivery of the cytotoxic agent, combined with the ability to work alongside immune-modulating drugs, can help overcome resistance mechanisms in tumors that are unresponsive to single-agent therapies. This makes MC-VC-PABC a valuable addition to multi-drug treatment regimens, which are often necessary for treating aggressive or refractory cancers.